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EXTENDED REPORT
Presence of anticitrullinated protein antibodies in a
large population-based cohort from the Netherlands
A van Zanten,1 S Arends,1 C Roozendaal,2 P C Limburg,2 F Maas,1 L A Trouw,3
R E M Toes,3 T W J Huizinga,3 H Bootsma,1 E Brouwer1
ABSTRACT
Objectives To determine the prevalence of
anticitrullinated protein antibodies (ACPAs) and their
association with known rheumatoid arthritis (RA) risk
factors in the general population.
Methods Lifelines is a multidisciplinary prospective
population-based cohort study in the Netherlands. Cross-
sectional data from 40 136 participants were used. The
detection of ACPA was performed by measuring anti-
CCP2 on the Phadia-250 analyser with levels ≥6.2 U/mL
considered positive. An extensive questionnaire was
taken on demographic and clinical information, including
smoking, periodontal health and early symptoms of
musculoskeletal disorders. RA was deﬁned by a
combination of self-reported RA, medication use for the
indication of rheumatism and visiting a medical specialist
within the last year.
Results Of the total 40 136 unselected individuals,
401 (1.0%) had ACPA level ≥6.2 U/mL. ACPA positivity
was signiﬁcantly associated with older age, female
gender, smoking, joint complaints, RA and ﬁrst degree
relatives with rheumatism. Of the ACPA-positive
participants, 22.4% had RA (15.2% had deﬁned RA
according to our criteria and 7.2% self-reported RA
only). In participants without RA, 311 (0.8%) were
ACPA-positive. In the non-RA group, older age, smoking
and joint complaints remained signiﬁcantly more
frequently present in ACPA-positive compared with
ACPA-negative participants.
Conclusions In this large population-based study, the
prevalence of ACPA levels ≥6.2 U/mL was 1.0% for the
total group and 0.8% when excluding patients with RA.
Older age, smoking and joint complaints were more
frequently present in ACPA-positive Lifelines participants.
To our knowledge, this study is the largest study to date
on ACPA positivity in the general, mostly Caucasian
population.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune
disease primarily targeting the joints.1 It is thought
that early treatment with disease-modifying anti-
rheumatic drugs (DMARDs) and possibly steroids
can prevent progression of the disease and may
even change or prevent the development of erosive
disease.2 A systemic review in early RA demon-
strated that longer symptom duration is associated
with more radiographic progression and lower
chance of DMARD-free sustained remission, sup-
porting the idea of a therapeutic ‘window of
opportunity’.3 Early detection of RA is therefore
crucial.
Previous studies have shown that persons with
arthralgia are at risk for developing RA.4 This risk
is even higher when the arthralgia is combined
with anticitrullinated protein antibody (ACPA) posi-
tivity.5 Patients with clinically suspected arthralgia
who show subclinical inﬂammation on MRI were
more often ACPA-positive than those without
inﬂammation on MRI, and were at high risk of
developing arthritis.6 Individuals with new non-
speciﬁc musculoskeletal symptoms but without
clinical synovitis were at high risk of rapidly pro-
gressing to RA when they tested ACPA-positive.7
Therefore, ACPA status can provide important
information on both diagnosis and prognosis.4 8–10
Depending on the method of ACPA detection
and the cut-off value used, 55–91% of patients
with RA are considered ACPA-positive compared
with 0–9% of healthy control subjects.11–15 It has
been shown that the switch to ACPA positivity can
occur up to 10 years before a patient develops arth-
ritis. Early serum samples from patients with classi-
ﬁed RA that were blood bank donors were
ACPA-positive in 31–41% of cases.11 15 16
Similarly, ﬁrst-degree relatives (FDRs) are more
likely ACPA-positive than regular controls.12–14 17
In a prospective study of 374 individuals who
reported arthralgia and had a positive ACPA and/or
IgM-rheumatoid factor (RF) status, 35% developed
arthritis after a median follow-up of 12 months.
Patients who developed arthritis were more often
ACPA-positive. However, the presence of antibodies
alone had insufﬁcient predictive power and needed
to be combined with other clinical parameters.5
The European League Against Rheumatism
Standing Committee on Investigative Rheumatology
has pointed out that better insights in early symp-
toms, ACPA testing and risk factors from patient
history are necessary for the development of a pre-
dictive model for RA in the years to come.18 19
To date, little is known about the presence of
ACPA in the general population. One recent
population-based study in Japan (n=9575) showed
an ACPA positivity prevalence of 1.7%20 and a
Turkish study (n=941) showed a prevalence of
1.0%.21 So far, only one other population-wide
study has been published on the prevalence of
ACPA positivity in Europe. In this Swedish twin
study (n=12 590) 2.8% were ACPA-positive,
including patients with RA.22 The exact relation-
ship between known RA risk factors, such as age,
gender, tobacco, joint complaints and having FDR
with RA20 23 24 and the development of ACPA
positivity needs to be further investigated.25
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The aim of the present study was to determine the prevalence
of ACPA positivity on a population level and to determine its
association with known RA risk factors. In this respect, we
investigated whether previously described risk factors for RA
and ACPA development were also more often present in indivi-
duals who were ACPA-positive within the Lifelines general
population.
MATERIALS AND METHODS
Study design and study population
Lifelines is a multidisciplinary prospective population-based
cohort study examining in a unique three-generation design the
health and health-related behaviours of 167 729 persons living
in the north-east region of the Netherlands. It employs a broad
range of investigative procedures in assessing the biomedical,
sociodemographic, behavioural, physical and psychological
factors which contribute to the health and disease of the general
population, with a special focus on multimorbidity and complex
genetics. Lifelines is a facility that is open for all researchers.
Information on application and data access procedure is sum-
marised on http://www.Lifelines.net.
Participants were recruited with the help of general practi-
tioners from both rural and non-rural areas and from different
economic classes. Participants were then asked to invite their
family members, making it into a three-generation population-
based cohort.26 This cohort well represents the northern,
mostly Caucasian, population of the Netherlands.27
Data for the present study were acquired at baseline visits
(2012–2013). Participants under 18 years of age were excluded.
An extensive questionnaire was handed in, physical examination
was performed and serum blood samples were collected. The
family history was obtained at the ﬁrst follow-up visit 1.5 years
later.26
The Lifelines Cohort Study was conducted according to the
principles of the Declaration of Helsinki, approved by the local
ethics committee of the University Medical Center Groningen
(UMCG), and all participants provided written informed
consent to participate in this study.
ACPA measurement
The detection of ACPA was performed by measuring anti-CCP2
(by EliA-cyclic citrullinated peptide (CCP) test) on the
Phadia-250 analyser. The measuring range (detection limit,
upper limit) for EliA CCP is from 0.4 EliA U/mL to ≥340 EliA
U/mL.
ACPA-CCP2 levels ≥6.2 U/mL were considered positive, based
on data of 400 apparently healthy controls obtained from
ThermoFisher Scientiﬁc. The cut-off value that is appropriate to
detect ACPA in the healthy population is not clear. As we wanted
to use the test to detect ACPA and not as a diagnostic test for RA,
the 99-centile cut-off value of ≥6.2 U/mL was chosen. Analyses
were also done using the 95-centile cut-off value of ≥4.3 U/mL
and the manufacturer’s cut-off value for RA of ≥10 U/mL.
Assessment of risk factors
Risk factors for RA and ACPA were determined using literature
analysis on PubMed. Access to data on these risk factors was
then assessed. Risk factors that could be included in the analyses
were age, gender, body mass index (BMI), use of tobacco,
alcohol, ﬁsh and/or sugar-sweetened soft drinks, periodontitis,
joint complaints and FDRs with rheumatism. For women nulli-
parity, menopausal status and hormone use, regular menses and
early menarche were assessed. Deﬁnitions of these risk factors
are shown in online supplementary table S1.
Deﬁnition of RA
Patients with RA were identiﬁed using data from the question-
naires. A participant was classiﬁed as a self-reported patient
with RA if the question on having RA was answered positive. A
participant was classiﬁed as patient with deﬁned RA if there was
either a combination of self-reported RA and the use of a
DMARD for the indication of ‘rheumatism’ or a combination of
self-reported RA, the use of steroids and/or non-steroidal anti-
inﬂammatory drugs (NSAIDs) for the indication of ‘rheumatism’
and having been to a medical specialist within the last year. An
overview of included DMARDs and NSAIDs is given in online
supplementary table S2.
Statistical analysis
Results were expressed as percentage of participants, mean±SD
or median (IQR) for categorical, normally distributed and non-
normally distributed data, respectively.
To assess whether the risk factors found in literature were cor-
related with ACPA positivity, participants were stratiﬁed accord-
ing to ACPA positivity. We performed the same analyses
excluding all patients with RA and deﬁned patients with RA
from the total populations. For all three analyses, χ2 tests,
Mann-Whitney U tests and univariable logistic regression were
performed to assess the differences.
Multivariable logistic regression (enter method, forward selec-
tion and backward elimination) was performed to assess which
factors were independent predictors of ACPA positivity.
Parameters were added into the model if they were found to be
signiﬁcantly associated with ACPA positivity in the previous ana-
lyses. If there was more than one variable for the same factor,
the strongest predictor of ACPA positivity was used.
Multivariable analysis was performed both for the entire group
and excluding deﬁned or self-reported patients with RA.
Statistical analysis was performed with IBM SPSS Statistics




In total, 40 136 participants were recruited for this study, of
whom 23 256 (58%) were female. The mean age was 44 (range
18–92). Among these participants, 838 (2.1%) had self-reported
RA and 138 (0.3%) were deﬁned as having RA (table 1, online
supplementary table S3).
Distribution of ACPA-CCP2 levels
Of all participants, 401 (1.0%) had an ACPA-CCP2 level
≥6.2 U/mL, 666 (1.7%) had an ACPA-CCP2 level ≥4.3 and 306
(0.8%) had an ACPA-CCP2 level ≥10 U/mL. The detailed distri-
bution of ACPA levels among participants is presented in table 2.
ACPA positivity (≥6.2 U/mL) was seen in 90 (10.7%) of
patients with self-reported RA and 61 (44.2%) of patients with
deﬁned RA. In participants without RA (non-RA group), 311
(0.8%) were ACPA-positive. The prevalence of both ACPA posi-
tivity and RA increased with age (table 3).
ACPA-positive versus ACPA-negative participants
ACPA-positive (≥6.2 U/mL) participants were signiﬁcantly older
and more often female compared with the ACPA-negative parti-
cipants. Furthermore, ACPA-positive participants had more pack
years of smoking and had less often never smoked. Joint com-
plaints and FDRs with rheumatism were also signiﬁcantly more
often reported. Moreover, ACPA-positive participants had
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substantially more frequently self-reported or deﬁned RA (table
4). When using a cut-off value of ≥4.3 U/mL or ≥10 U/mL,
similar results were found. Additionally for ≥10 U/mL,
ACPA-positive participants reported signiﬁcantly less use of
sugar-sweetened soft drinks and women were less often nullipar-
ous (data not shown).
In the population without RA or self-reported RA, older age,
smoking and joint complaints remained associated with ACPA
positivity (≥6.2 U/mL) (table 5). In this group, gender, BMI,
alcohol intake, ﬁsh intake, sugar-sweetened soft drink intake,
periodontitis and FDR with rheumatism were comparable
between ACPA-positive and ACPA-negative participants. Within
the female study population, nulliparity, menopausal status and
hormone use, early menarche and regular menses were not
associated with ACPA positivity. When a cut-off value of ≥4.3
U/mL or ≥10 U/mL was used, similar results were found.
Independent predictors of ACPA positivity
Using multivariable analysis, pack years of smoking was the
strongest smoking variable predicting ACPA positivity and not
smoking status (never, former or current). Gender, pack years of
smoking and joint complaints were independent predictors of
ACPA positivity (table 6). When excluding self-reported and/or
deﬁned RA participants, only gender and pack years remained
statistically signiﬁcant.
DISCUSSION
In this large cross-sectional population-based study (n=40 136),
the prevalence of ACPA positivity was 1.0% on a population
level and 0.8% when excluding RA participants, using
ACPA-CCP2 ≥6.2 U/mL (99th centile) as the cut-off point.
Three previous studies investigated the prevalence of ACPA
positivity in the general population. In a Japanese study20
(n=9575), the reported prevalence was 1.7% in autoimmune
disease-free volunteers aged 30–75 years using a Japanese
CCP2-kit. A Turkish study21 (n=941) found a prevalence of
1.0% in a healthy population using a EuroDiagnostica second-
generation anti-CCP antibody assay. A twin study in Sweden
found an (n=12 590) ACPA positivity (including patients with
RA) of 2.8% using an anti-CCP2 ELISA EuroDiagnostica
assay.22 However, as the ﬁrst two studies were performed in
non-Caucasian populations and all studies used different
ACPA-CCP assays with different cut-off levels, it is difﬁcult to
compare their results with our study.
In our study population, ACPA positivity was signiﬁcantly
associated with several risk factors for RA and/or ACPA as
found in literature.
First, we found an association between older age and ACPA
positivity, both in the entire group and in the non-RA group. In
agreement with our study, the Japanese study found that in
non-RA individuals ACPA positivity was associated with older
age.20
Second, we found an association between female gender and
ACPA positivity, which has not yet been well documented,
although RA is more prevalent among women.28 In our study,
female gender remained signiﬁcantly associated with ACPA posi-
tivity after correcting for age, smoking and joint complaints.
However, when excluding patients with RA, female gender was
no longer associated with ACPA positivity.
Third, we found an association of both smoking status and
pack years with ACPA positivity, which was reported in previous
studies as well. A Malaysian case-control study (n=1056 vs
1416) found that ever-smokers had an increased risk of develop-
ing ACPA-positive RA compared with never smokers. A relation










≥6.2 U/mL 1.0 0.8 10.7 44.2
<4.3 U/mL 98.3 98.5 88.5 55.1
4.3–6.2 U/mL 0.7 0.7 0.8 0.7
6.2–10 U/mL 0.2 0.2 0.4 0.7
≥10 U/mL 0.8 0.6 10.3 43.5
RA, rheumatoid arthritis.
Table 1 Baseline characteristics: all participants
All (n=40 136)
Age (years) 44 (34–51)
Gender (female) 58%
BMI (kg/m2) 25 (23–28)
Obesity 15%





Alcohol intake (g/day) 3 (0–11)
Fish intake (servings/month) 5 (2–9)
Sugar-sweetened soft drink intake (glasses/month) 6 (0–22)
Periodontitis (self-reported) 12%
Joint complaints: pain and/or stiffness in hands and/or feet 21%
Joint complaints: both pain and stiffness in hands and/or feet 12%
FDR with rheumatism 14%
Self-reported RA 2.1%
Defined RA 0.3%




Postmenopausal and hormone use 4%
Postmenopausal and no hormone use 33%
Regular menses 77%
Age of menarche ≤10 2%
Data are presented as median (IQR) for continuous variables and percentages for
categorical variables.
BMI, body mass index; FDR, first-degree relative; RA, rheumatoid arthritis.
Table 3 The distribution of the Lifelines population, anticitrullinated
protein antibodies (ACPA) positivity, self-reported rheumatoid arthritis










18–30 16.5 0.6 0.5 0.1
30–40 19.7 0.8 1.0 0.1
40–50 34.4 0.9 2.0 0.3
50–60 19.7 1.4 3.3 0.7
60+ 9.7 1.5 5.0 0.8
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between pack years and the risk of ACPA-positive RA was also
seen, with an OR of 3.3 for <20 pack years and an OR of 5.2
for at least 20 pack years.29 This is in contrast to the Japanese
population-based study, where only a signiﬁcant association
between the amount of smoking and high levels of ACPA was
found.20
Finally, joint complaints were found to be an independent
risk factor for ACPA positivity, even with the limited joint com-
plaint questions that were asked to the participants. Also, in
non-RA participants the presence of joint complaints stayed sig-
niﬁcantly different between ACPA-positive and ACPA-negative
participants after correcting for age, gender and smoking.
FDRs of patients with RA were found to be more often
ACPA-positive.14 In our study population, having FDRs with
rheumatism was also associated with ACPA positivity. However,
in the non-RA group this was no longer the case. One possible
explanation for FDR with rheumatism not being associated with
ACPA positivity in the non-RA group in our study would be the
questionnaires asking for FDRs with rheumatism instead of RA.
Other risk factors for RA and ACPA as found in literature
were not signiﬁcantly associated with ACPA positivity in our
Lifelines population. In the Nurses’ Health Study, overweight
and BMI were signiﬁcantly associated with RA.30 In our study,
BMI was not associated with ACPA positivity. Alcohol non-use
has been associated with ACPA positivity and/or higher ACPA
titres and self-reported periodontitis has been associated with
RA in previous studies,14 31–33 but we could not conﬁrm these
ﬁndings. Periodontitis was assessed in the Lifelines population
using a questionnaire and may therefore have not been fully
accurate. Furthermore, it has been described that within a
person’s diet ﬁsh intake (n=1889) would protect against and
sugar-sweetened soft drinks (n=79 570) would be a risk factor
for RA.34 35 We could not replicate these results.
The female-based variables nulliparity, menopausal status,
regular menses and early menarche were all not signiﬁcantly
associated with ACPA positivity, both in the entire study popula-
tion as well as after excluding RA participants. These results are
in agreement with recent literature.28
The main limitations of the present study were ﬁrst the fact
that the ACPA cut-off value is not a ‘ﬁxed’ value and second
that it could not be veriﬁed by medical records whether partici-
pants had RA. The ACPA cut-off value was difﬁcult to deter-
mine since all tests and their speciﬁcities and sensitivities are
based on using the test as a diagnostic tool for RA. However,
after consulting the manufacturer and taking into account data
they provided on ACPA levels of 400 apparently healthy





participants (n=39 735) p Value
Age (years) 44 (34–51) 48 (39–54) 44 (34–51) <0.001
Gender (female) 58% 65% 58% 0.005
BMI (kg/m2) 25 (23–28) 26 (23–28) 25 (23–28) 0.431
Obesity 15% 14% 15% 0.611
Smoking: pack years 0 (0–8) 2 (0–13) 0 (0–8) <0.001
Smoking status <0.001
Never smoker 49% 39% 49%
Former smoker 30% 36% 30%
Current smoker 21% 25% 21%
Alcohol (g/day) 3 (0–11) 4 (0–11) 3 (0–11) 0.571
Alcohol intake, categories 0.396
None to 5 g/day 59% 56% 59%
5 g/day to <10 g/day 16% 18% 16%
10 g/day or more 25% 25% 25%
Fish intake (servings/month) 5 (2–9) 5 (2–9) 5 (2–9) 0.727
Sugar-sweetened soft drink intake (glasses/month) 6 (0–22) 5 (0–17) 6 (0–22) 0.053
Periodontitis (self-reported) 12% 14% 12% 0.263
Joint complaints: pain and/or stiffness in hands and/or feet 21% 39% 21% <0.001
Joint complaints: both pain and stiffness in hands and/or feet 12% 29% 12% <0.001
FDR with rheumatism 14% 18% 14% 0.014
Self-reported RA 2% 22% 2% <0.001
Defined RA 0% 15% 0% <0.001
In women (n=23 256)
Nulliparity 27% 23% 27% 0.182
Menopausal status, categories 0.454
Premenopausal 63% 68% 63%
Postmenopausal and hormone use 4% 3% 4%
Postmenopausal and no hormone use 33% 29% 34%
Regular menses 77% 79% 77% 0.707
Age of menarche ≤10 2% 3% 2% 0.492
Data are presented as median (IQR) for continuous variables and percentages for categorical variables.
ACPA, anticitrullinated protein antibodies; BMI, body mass index; FDR, first-degree relative; RA, rheumatoid arthritis.
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controls, we decided that 6.2 U/mL (99th centile) is an appro-
priate cut-off value. This cut-off value was lower than the
cut-off value used in the diagnostic test for RA (≥10 U/mL) in
order to get an insight into the presence of ACPA.
Second, many people regard themselves as having RA when
they experience joint complaints, but they have not always
been diagnosed by a doctor. Therefore, we checked RA-speciﬁc
medication use and visits to a medical specialist in these
patients with self-reported RA. As this database was large, the
indexing that was used to ﬁnd the medication of interest may
have missed some patients with RA. To make the selection of
patients with deﬁned RA more secure, the indications of the
drugs were checked by hand. Since ACPA positivity shows a
steep curve from non-RA to self-reported RA to deﬁned RA,
we concluded that our deﬁnition is a good estimate for RA.
However, the prevalence we found for deﬁned RA is somewhat
low, which makes it likely that some patients were missed
using this deﬁnition.36 Additionally, the prevalence of ACPA
positivity was only 44% in our deﬁned RA population,
whereas previous literature has shown that 55–91% of patients
with RA are considered ACPA-positive.11–15 This means that
our deﬁned RA group likely also contains some individuals
without RA. It is important to realise that our deﬁnition was
not RA classiﬁed by a rheumatologist and misclassiﬁcation
could have occurred.
Another limitation of this study is that even though we did
ﬁnd signiﬁcant differences between the different groups, the
ORs were only small. The clinical use of those small differences
should be interpreted with caution. Moreover, the present ana-
lysis was cross-sectional and therefore, the causality of our ﬁnd-
ings cannot be claimed.
Unfortunately, we did not yet have access to genetic informa-
tion about our participants, even though this is seen as an
important factor for determining the switch to RA.37
Furthermore, our data on joint complaints was limited. It would
have been helpful if more speciﬁc RA symptoms were assessed
at baseline. Also data on breast feeding,38 birth weight,39 inter-
stitial lung disease,40 C reactive protein41 and other relevant
autoantibodies like RF and anti-carbamylated protein (CarP)
antibodies42 were not available.
To our knowledge, this is the ﬁrst study that measured ACPA
in >40 000 participants from a general, mostly Caucasian
population.
As the Lifelines study is a prospective longitudinal cohort
study with 30-year follow-up duration, it will be possible to
gain follow-up information on our study population. It will be
interesting to see which participants will eventually develop RA.
Will the participants who reported having RA but did not yet
have deﬁned RA develop deﬁned RA? These future results from
the Lifelines cohort study will help us in improving the existing





participants (n=38 987) p Value
Age (years) 44 (34–51) 46 (35–52) 44 (34–51) 0.017
Gender (female) 58% 62% 58% 0.103
BMI (kg/m2) 25 (23–28) 25 (23–28) 25 (23–28) 0.834
Obesity 15% 13% 15% 0.444
Smoking: pack years 0 (0–8) 1 (0–11) 0 (0–8) <0.001
Smoking status 0.006
Never smoker 49% 40% 49%
Former smoker 30% 35% 30%
Current smoker 21% 25% 21%
Alcohol (g/day) 3 (0–11) 3 (0–9) 3 (0–11) 0.861
Alcohol intake, categories 0.499
None to 5 g/day 59% 57% 59%
5 g/day to <10 g/day 16% 18% 16%
10 g/day or more 25% 24% 25%
Fish intake (servings/month) 5 (2–9) 5 (2–9) 5 (2–9) 0.754
Sugar-sweetened soft drink intake (glasses/month) 6 (0–22) 6 (0–20) 6 (0–22) 0.270
Periodontitis (self-reported) 12% 14% 12% 0.284
Joint complaints: pain and/or stiffness in hands and/or feet 20% 26% 20% 0.018
Joint complaints: both pain and stiffness in hands and/or feet 11% 15% 11% 0.026
FDR with rheumatism 14% 15% 14% 0.476
In women (n=22 727)
Nulliparity 27% 28% 27% 0.926
Menopausal status, categories 0.145
Premenopausal 63% 73% 63%
Postmenopausal and hormone use 4% 4% 4%
Postmenopausal and no hormone use 33% 23% 34%
Regular menses 78% 78% 78% 0.984
Age of menarche ≤10 2% 3% 2% 0.302
Data are presented as median (IQR) for continuous variables and percentages for categorical variables.
ACPA, anticitrullinated protein antibodies; BMI, body mass index; FDR, first-degree relative; RA, rheumatoid arthritis.
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prediction models for RA, in order to facilitate early recognition
of RA and act on it even in the early ‘window of opportunity’.
In conclusion, this large, cross-sectional, population-based
study in 40 136 mostly Caucasian Lifelines participants showed
that the prevalence of ACPA-CCP2 positivity is 1.0% for the
total population and 0.8% when excluding patients with RA
(ACPA cut-off ≥6.2 U/mL). The strong association of ACPA
positivity with RA and joint complaints supports the importance
of ACPA screening in persons with joint/musculoskeletal com-
plaints. Moreover, older age and smoking were associated with
ACPA positivity and possibly play a pathogenic role in the devel-
opment of ACPA positivity.
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Table 6 Univariable and multivariable logistic regression for RA risk factors and ACPA positivity (≥6.2 U/mL) in all participants and after
exclusion of RA participants
Univariable Multivariable
OR 95% CI p Value OR 95% CI p Value
All participants (n=40 136)
Age (years) 1.023 1.014 to 1.031 <0.001 1.013 1.003 to 1.022 0.007
Gender (female) 1.342 1.092 to 1.649 0.005 1.325 1.069 to 1.643 0.010
Smoking: pack years 1.023 1.015 to 1.030 <0.001 1.018 1.009 to 1.026 <0.001
Pack years, categories (%)
Never to 10 Ref. Ref. Ref.
>10–20 1.136 0.835 to 1.546 0.416
>20 2.311 1.763 to 3.030 <0.001
Smoking status
Never smoker Ref. Ref. Ref.
Former smoker 1.532 1.221 to 1.923 0.000
Current smoker 1.499 1.164 to 1.929 0.002
Alcohol intake (g/day) 1.001 0.991 to 1.011 0.852
Joint complaints: pain and/or stiffness in hands and/or feet) 2.384 1.945 to 2.923 <0.001
Joint complaints: both pain and stiffness in hands and/or feet 2.976 2.390 to 3.705 <0.001 2.556 2.033 to 3.215 <0.001
Self-reported RA 15.083 11.800 to 19.281 <0.001
Defined RA 92.404 64.953 to 131.456 <0.001
Participants with RA excluded (n=39 298)
Age (years) 1.010 1.001 to 1.020 0.032 1.003 0.993 to 1.014 0.517
Gender (female) 1.211 0.962 to 1.524 0.104 1.289 1.014 to 1.639 0.038
Smoking: pack years 1.019 1.010 to 1.028 <0.001 1.019 1.009 to 1.028 <0.001
Pack years, categories (%)
Never to 10 Ref. Ref. Ref.
>10–20 1.070 0.752 to 1.524 0.706
>20 1.915 1.379 to 2.659 <0.001
Smoking status
Never smoker Ref. Ref. Ref.
Former smoker 1.438 1.111 to 1.863 0.006
Current smoker 1.465 1.102 to 1.946 0.008
Alcohol intake (g/day) 0.995 0.983 to 1.008 0.463
Joint complaints: pain and/or stiffness in hands and/or feet) 1.364 1.055 to 1.764 0.018
Joint complaints: both pain and stiffness in hands and/or feet 1.422 1.040 to 1.943 0.027 1.275 0.923 to 1.762 0.140
Data are presented as ORs and CIs of the enter method. Forward and backward analyses resulted in comparable models with the same variables.
ACPA, anticitrullinated protein antibodies; RA, rheumatoid arthritis.
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